Review of the renal endpoints used in cardiovascular safety clinical trials in type 2 diabetes mellitus patients and their importance in primary care.

Chronic kidney disease (CKD) is one of the most common complications of type 2 diabetes mellitus (T2DM). Furthermore, CKD confers a considerable increase in the risk of cardiovascular (CV) morbidity and mortality. In line with the need to improve knowledge in this field, this article aims to describe the renal endpoints used in the different cardiovascular outcome trials (CVOTs).

[Relationship between the degree of glycemic control and diabetes characteristics and hyperglycemia treatment in type 2 diabetes. DIABES Study].

Background And Objective: To evaluate the relationship between the degree of glycemic control and the features of the disease and glucose-lowering treatment in patients with type 2 diabetes mellitus in Spain.

Patients And Methods: Cross-sectional epidemiological study in Spain with consecutive sampling. We recorded demographic and clinical variables of patients who were followed up in the center for >12 months.

Clinical applicability of B-type natriuretic peptide in patients with suspected heart failure in primary care in Spain: the PANAMA study.

Aim: To assess the predictive value of B-type natriuretic peptide (BNP) in the diagnosis of heart failure (HF) in a primary-care setting in Spain.

Methods: PANAMA was a multicenter and cross-sectional study. Patients ≥18 years of age with a clinical diagnosis of HF (Framingham criteria) were consecutively included in the study by primary-care investigators.

Pulse pressure and the metabolic syndrome in patients with hypertension.

The authors examined the clinical profile of the hypertensive population with the metabolic syndrome (MetS) and elevated pulse pressure (PP) in a sample of 5866 patients (3291 women and 2575 men) included in a large hypertension survey performed in primary care setting. Elevated PP was defined as >or=80 mm Hg in women and >or=75 mm Hg in men; 92.7% of women and 87.

[Impact of the presence of cardiovascular disease on blood pressure and lipid control in the hypertense population attended in primary care].

Objectives: To determine the impact of cardiovascular disease (CVD) (heart failure, ischaemic heart disease, stroke, renal insufficiency, and peripheral arterial disease) on blood pressure (BP) and LDL-cholesterol (LDL-C) control in hypertense patients.

Design: We analysed the subset of patients with CVD from those included in the PRESCOT study (a cross-sectional study of hypertense patients attended in primary care).

Setting: A total of 2000 primary care physicians participated in the study.

[Blood pressure findings in Spanish dyslipidemic primary-care patients. LIPICAP-PA Study].

Background And Objectives: Despite the well-known significant relationship between blood pressure and cardiovascular mortality, few data are available on the blood pressure characteristics of dyslipidemic patients. The aims of this study were to determine the blood pressure characteristics of dyslipidemic patients being treated in primary care, and to identify factors associated with poor blood pressure control.

Methods: This multicentre cross-sectional study involved patients of both sexes aged > or =18 years who were diagnosed with dyslipidemia (i.

Prevalence of the metabolic syndrome in patients with hypertension treated in general practice in Spain: an assessment of blood pressure and low-density lipoprotein cholesterol control and accuracy of diagnosis.

This study was designed to evaluate whether primary care physicians in Spain accurately diagnose the metabolic syndrome in hypertensive patients, to define the profile and management of these patients in clinical practice, and to ascertain the level of blood pressure and low-density lipoprotein cholesterol control. Data were analyzed from a cross-sectional survey involving 12,954 patients with hypertension (Prevención Cardiovascular en España en Atención Primaria: Intervención Sobre el Colesterol en Hipertensión [PRESCOT] study), wherein 52% of the cohort fulfilled the National Cholesterol Education Program-Adult Treatment Panel criteria for the metabolic syndrome. The majority of patients (54.

[Adequacy of the treatment of hypertensive patients with metabolic syndrome].

Background And Objective: The aim of this study was to know the treatment of hypertensive patients with metabolic syndrome (MetS) attended in primary care setting, as well as the blood pressure and LDL-cholesterol (LDL-c) rates, and to compare these data with those of the hypertensive population without MetS.

Patients And Method: We analyzed the subset of patients with MetS from those included in the PRESCOT study (a cross-sectional study of hypertensive subjects >18 years attended in primary care). The PRESCOT population was composed by 12,954 patients (49.

Blood pressure and lipid goal attainment in the hypertensive population in the primary care setting in Spain.

Although blood pressure (BP) control is crucial in hypertensive patients, clinical practice guidelines agree that the goal of treatment should be aimed at not only decreasing BP but reducing global cardiovascular risk. The aim of this cross-sectional study was to evaluate BP, low-density lipoprotein cholesterol (LDL-C), and composite control rates in a hypertensive population in a primary care setting in Spain. Good BP control was defined as <140/90 mm Hg (<130/80 mm Hg for diabetics).

Carotid angioplasty with cerebral protection and stenting: report of 164 patients (194 carotid percutaneous transluminal angioplasties).

Background: The introduction of cerebral protection devices with systematic stent placement has changed the nature of carotid artery stenosis treatment, reducing the immediate periprocedural complications and delayed restenosis.

Methods: We treated 164 patients with 194 carotid artery stenosis procedures; 92% of them were symptomatic patients.

Results: The morbidity rate of our series was 1.